Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Liabilities and Shareholders Equity: 2023-2024

Historic Liabilities and Shareholders Equity for Silence Therapeutics (SLN) over the last 2 years, with Dec 2024 value amounting to $202.6 million.

  • Silence Therapeutics' Liabilities and Shareholders Equity was N/A to $146.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $700.0 million, marking a year-over-year change of. This contributed to the annual value of $202.6 million for FY2024, which is 69.64% up from last year.
  • According to the latest figures from FY2024, Silence Therapeutics' Liabilities and Shareholders Equity is $202.6 million, which was up 69.64% from $119.4 million recorded in FY2023.
  • Silence Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $202.6 million for FY2024, and its period low was $119.4 million during FY2023.